Trial reportJACC. Heart failure2025
Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute HF: The REHAB-HF Trial.
Trial report in JACC. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale.American heart journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundA multidomain physical rehabilitation intervention (REHAB-HF [Rehabilitation Therapy in Older Acute Heart Failure Patients] intervention) has been associated with significant improvements in physical function and quality of life (QOL) among older patients with acute decompensated heart failure (ADHF).
objectivesThis study aims to evaluate sex differences in the treatment effect of a multidomain rehabilitation intervention among participants of the REHAB-HF trial.
methodsIn this prespecified secondary analysis of the REHAB-HF trial, sex differences in the treatment effect of the REHAB-HF intervention (vs attention control) on key 3-month outcomes of the Short Physical Performance Battery (SPPB, primary), frailty burden, 6-minute walking distance (6MWD), and QOL were assessed. Statistical significance for treatment effect interaction (sex∗intervention) was set at 0.1.
resultsAmong the 349 trial participants, female patients (n = 183) had a significantly lower baseline SPPB score and 6MWD and a higher frailty burden than male patients (n = 166). Female (vs male) participants had a significantly greater improvement in SPPB (effect size: 1.9 [95% CI: 1.1-2.7] vs 1.0 [95% CI: 0.1-1.8]; P for interaction = 0.1) and frailty burden, as assessed by Fried phenotype criteria (effect size: -0.5 [95% CI: -0.9 to -0.2] vs 0.00 [95% CI: -0.4 to 0.4]; P for interaction = 0.04) with the REHAB-HF intervention. The magnitude of the improvement in 6MWD and QOL (Kansas City Cardiomyopathy Questionnaire score) with the REHAB-HF intervention was also greater among female (vs male) participants without a significant treatment effect interaction by sex. There was no significant difference in rates of adverse clinical outcomes associated with the intervention across both sex groups. There was no difference in intervention adherence by sex.
conclusionsFemale (vs male) participants with ADHF had a significantly greater improvement in physical function in response to the REHAB-HF intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.